Pear Therapeutics raised $20 M in its Series A round in February 2016, followed by $50 M in Series B in January 2018, then $64 M in Series C in January 2019, $50 M via debt financing in July 2020, $80 M in Series D in December 2020, and $125 M in a post-IPO equity round in December 2021, bringing its total funding to approximately $266 M. The company reached a valuation of about $1.6 B as of June 2021, focusing on software-based therapeutic solutions in the healthcare IT sector.